Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study

Fig. 2

Antitumor activity in patients with EGFR wild-type and EGFR mutated tumors assessed per RECIST v1.1 by investigator. a Best percentage change from baseline in target lesion size in cohorts 1 to 4 is presented by cohort. b Best percentage change from baseline in target lesion size in cohorts 1 to 4 by histology. c Best percentage change from baseline in target lesion size in cohort 5. Abbreviations: Q QL1706, Pac paclitaxel, Pem pemetrexed, C carboplatin, B bevacizumab

Back to article page